Ditchcarbon
  • Contact
  1. Organizations
  2. Biogen
Public Profile
Pharmaceutical Preparation Manufacturing
US
updated 12 days ago

Biogen

Company website

Biogen Inc., a leading biotechnology company headquartered in the United States, has been at the forefront of neurological disease research since its founding in 1978. With a strong presence in North America, Europe, and Asia, Biogen focuses on developing innovative therapies for conditions such as multiple sclerosis, spinal muscular atrophy, and Alzheimer’s disease. Renowned for its pioneering work in monoclonal antibodies, Biogen's core products include the multiple sclerosis treatments Tecfidera and Ocrevus, which are distinguished by their efficacy and safety profiles. The company has achieved significant milestones, including the first FDA approval of a treatment for spinal muscular atrophy in 2016. As a key player in the biotechnology industry, Biogen continues to push the boundaries of science, solidifying its market position through a commitment to research and development, and a robust pipeline of potential therapies.

DitchCarbon Score

How does Biogen's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

97

Industry Average

Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

31

Industry Benchmark

Biogen's score of 97 is higher than 98% of the industry. This can give you a sense of how well the company is doing compared to its peers.

98%

Let us know if this data was useful to you

Biogen's reported carbon emissions

In 2024, Biogen reported total carbon emissions of approximately 324,178,000 kg CO2e globally, with a significant portion, about 267,059,000 kg CO2e, classified under Scope 3 emissions. Notably, the company disclosed zero emissions for Scope 1 and Scope 2, indicating a focus on indirect emissions primarily from its supply chain and business travel. The breakdown of Scope 3 emissions includes business travel (about 18,067,000 kg CO2e) and purchased goods and services (approximately 184,441,000 kg CO2e). Biogen has set ambitious climate commitments, aiming for net-zero greenhouse gas emissions across its entire value chain by 2045. The company has established near-term targets to reduce absolute Scope 1 and 2 emissions by 55% by 2032, using 2019 as the baseline year. Furthermore, it aims to achieve a 100% reduction in these emissions by 2040. For Scope 3 emissions, Biogen targets a 90% reduction by 2045. These commitments align with the Science Based Targets initiative (SBTi) standards, reinforcing Biogen's dedication to sustainable practices within the pharmaceutical and biotechnology sector. The company is also working towards ensuring that 80% of its suppliers, by spend, have science-based targets by 2025, further enhancing its sustainability efforts.

Unlock detailed emissions data

Access structured emissions data, company-specific emission factors, and source documents

2015201620172018201920202021202220232024
Scope 1
60,179,000
00,000,000
00,000,000
00,000,000
00,000,000
-
00,000,000
00,000,000
00,000,000
00,000,000
Scope 2
187,000
000,000
00,000
00,000
000,000
000,000
000,000
000,000
000,000
000,000
Scope 3
262,358,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000

Industry emissions intensity

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Biogen's primary industry is Pharmaceutical Preparation Manufacturing, which is very low in terms of carbon intensity compared to other industries.

Location emissions intensity

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for Biogen is in US, which has a low grid carbon intensity relative to other regions.

Reduction initiatives & disclosure networks

Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.

Biogen is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Similar Organizations

Roche Holding AG

CH
•
Pharmaceutical Preparation Manufacturing
Updated 2 days ago

Grifols

ES
•
Pharmaceutical Preparation Manufacturing
Updated 10 days ago

Celgene Corporation

US
•
Pharmaceutical Preparation Manufacturing
Updated 22 days ago

Zoetis

US
•
Pharmaceutical Preparation Manufacturing
Updated 3 days ago

Astra Zeneca

GB
•
Pharmaceutical Preparation Manufacturing
Updated 2 days ago

Gilead Sciences

US
•
Pharmaceutical Preparation Manufacturing
Updated 1 day ago

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers

Ditchcarbon
v251005.1
[email protected]+44 203 475 7875Ditch Carbon Ltd167-169 Great Portland StreetLondon W1W 5PF
UL Solutions verification badge
CDP logo
Gartner Cool Vendor 2025 badge
ProductPortalScope 3 Tool FunctionalityDataIntegrationsPricing
CustomersHaleonGrant ThorntonHikmaRead all stories
SolutionsProcurement teamsSustainability teamsPlatform ownersCarbon accountants
ResourcesCalculation MethodologyDocumentationBlogFAQOrganizationsIndustriesSBTI APITrust CentreChangelog
AboutTeamCareersLicense AgreementPrivacy